Shots:
- Polpharma Biologics has reported that its JV company, Bioeq collaborates with Teva to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU, Canada, Israel & New Zealand
- The launch of biosimilar ranibizumab may increase market competition, reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis while FYB201 was originally licensed from Formycon AG
- The recent agreement with Teva complements a previous agreement with Coherus BioScience for commercialization in the US. Lucentis is a mAb fragment that has been approved to treat wet AMD
Click here to read full press release/ article | Ref: Businesswire | Image: Bioeq
The post Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar, ranibizumab) first appeared on PharmaShots.
